Pharmaceutical Earnings

Amgen, Inc. (NASDAQ: AMGN) Tuesday earnings report was of "poor-quality" and the company doesn't have any near-term catalysts to support the stock, analysts at BMO Capital Markets said. Analyst M. Ian Somaiya downgraded Amgen's stock rating from Outperform to Market Perform...

Shares of Biogen Inc (NASDAQ: BIIB) were trading higher by more than 5 percent early Wednesday morning after the company reported its fourth quarter and full year results. Biogen earned $4.50 per share in the fourth quarter on revenue of $2.839 billion. Wall Street analysts were expecting the...